Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

Cancer Science

Volumn 103, Issue 12, 2012, Pages 2135-2138

  Okamoto, Isamu ^a   Arao, Tokuzo ^b   Miyazaki, Masaki ^a   Satoh, Taroh ^a   Okamoto, Kunio ^a   Tsunoda, Takuya ^c   Nishio, Kazuto ^b   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Research and Development Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ELPAMOTIDE; HLA A ANTIGEN; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE EXPRESSION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; MALE; MAXIMUM TOLERATED DOSE; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RHINOPHARYNGITIS; SOLID TUMOR; STOMACH CANCER; T LYMPHOCYTE; THYROID CANCER; VOMITING;

AGED; CANCER VACCINES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HLA-A24 ANTIGEN; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; VACCINES, SUBUNIT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84870692106     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12014     Document Type: Article

References (21)

1. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
3. Tie J, Desai J. Antiangiogenic therapies targeting the vascular endothelial growth factor signaling system. Crit Rev Oncog 2012; 17: 51-67.
4. Li Y, Wang MN, Li H et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002; 195: 1575-84.
5. Niethammer AG, Xiang R, Becker JC et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-75.
6. Wada S, Tsunoda T, Baba T et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005; 65: 4939-46.
7. Miyazawa M, Ohsawa R, Tsunoda T et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010; 101: 433-9.
8. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 2000; 92: 205-16.
9. Yamanaka R, Arao T, Yajima N et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006; 25: 5994-6002.
10. Yamada Y, Arao T, Gotoda T et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 2008; 99: 2193-9.
11. Ishizaki H, Tsunoda T, Wada S et al. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 2006; 12: 5841-9.
12. Matejuk A, Leng Q, Chou ST et al. Vaccines targeting the neovasculature of tumors. Vasc Cell 2011; 3: 7.
13. Cormier JN, Hijazi YM, Abati A et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75: 517-24.
14. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999; 5: 178-86.
15. Paschen A, Mendez RM, Jimenez P et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103: 759-67.
16. Bertolini F, Shaked Y, Mancuso P et al. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6: 835-45.
17. Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev 2008; 27: 415-34.
18. Monsurro V, Marincola FM. Microarray analysis for a comprehensive immunological-status evaluation during cancer vaccine immune monitoring. J Biomed Biotechnol 2011; 2011: 307297.
19. Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 3045-54.
20. Norden-Zfoni A, Desai J, Manola J et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 2643-50.
21. Okamoto I, Kaneda H, Satoh T et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9: 2825-33.